查找临床试验
已按「食管癌」检索，对应国际通用词 esophageal cancer
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 11:24，每 5 分钟自动同步正在招募II 期中国有中心NCT06056336
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
China
年龄 18 Years – 75 Years
Guo Xufeng
正在招募II 期中国有中心NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
United States、Australia、Canada、China、Denmark 等 11 国
年龄 18 Years – 不限
Bayer
正在招募不适用中国有中心NCT07251114
AI-assisted Endoscopic Ultrasound Grading of Early Esophageal Cancer Invasion Depth: A Multicenter, Prospective, Randomized Cohort Study
China
年龄 18 Years – 不限
Fujian Provincial Hospital
正在招募不适用中国有中心NCT06602843
Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
China
年龄 18 Years – 75 Years
Anhui Provincial Hospital
正在招募II 期中国有中心NCT05515315
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
China
年龄 18 Years – 70 Years
Fuzhou General Hospital
正在招募II 期中国有中心NCT07796113
Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC
China
年龄 18 Years – 75 Years
First Affiliated Hospital Xi'an Jiaotong University
正在招募II 期中国有中心NCT06869213
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
China
年龄 18 Years – 75 Years
Peking University Cancer Hospital & Institute
正在招募不适用中国有中心NCT06715839
Target-specific immunoPET Imaging of Digestive System Carcinoma
China
年龄 18 Years – 75 Years
RenJi Hospital
正在招募III 期中国有中心NCT03731442
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
China
年龄 16 Years – 70 Years
Chinese Academy of Medical Sciences
正在招募II 期中国有中心NCT05507411
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
China
年龄 18 Years – 75 Years
Zhejiang Cancer Hospital
正在招募I 期 / II 期中国有中心NCT06173986
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
China
年龄 18 Years – 75 Years
Shanghai Chest Hospital
正在招募I 期中国有中心NCT07181473
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
United States、China
年龄 18 Years – 不限
Phrontline Biopharma